These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 9929518)

  • 1. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
    Stearns RA; Chakravarty PK; Chen R; Chiu SH
    Drug Metab Dispos; 1995 Feb; 23(2):207-15. PubMed ID: 7736913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
    Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
    Taavitsainen P; Kiukaanniemi K; Pelkonen O
    Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
    Yun CH; Lee HS; Lee H; Rho JK; Jeong HG; Guengerich FP
    Drug Metab Dispos; 1995 Feb; 23(2):285-9. PubMed ID: 7736926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
    Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
    Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways.
    Bort R; Macé K; Boobis A; Gómez-Lechón MJ; Pfeifer A; Castell J
    Biochem Pharmacol; 1999 Sep; 58(5):787-96. PubMed ID: 10449188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
    Taguchi K; Konishi T; Nishikawa H; Kitamura S
    Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.